@FiercePharma: Biggest new news Monday: Irate Teva reps vow to strike against Israeli job cuts. Story | Follow @FiercePharma
@CarlyHFierce: Sanofi nabs OTC nod for Nasacort amid consumer healthcare push. ICYMI yesterday | Follow @CarlyHFierce
> The U.K.'s cost-effectiveness watchdog didn't budge on its rejection of Cell Therapeutics' ($CTIC) lymphoma drug Pixuvri, despite the company's offer of a discount. Report
> Antares Pharma won FDA approval for its drug Otrexup, a once-a-week, self-injected version of the standard oral treatment for rheumatoid arthritis and psoriasis, methotrexate. Report (sub. req.)
> The British pharma market is expected to hit $31.7 billion by 2010, GlobalData says, with good access to healthcare and a growing disease burden fueling growth. Report
> Cancer cases cost Europe €126 billion in 2009, including a €51 billion outlay on healthcare expenses; spending varied widely, from €16 per citizen in Bulgaria to €184 per capita in Luxembourg. Report
> A Madrid court yesterday heard Spain's first lawsuit against Germany's Grunenthal, which made the morning sickness drug thalidomide that caused birth defects in many babies. Report
> Of the 66 drugmakers that have received warning letters from the FDA since 2010, 12% were Indian companies, the Daily Mail found. Report
> Amid shortages of its usual execution drugs, Florida plans to execute a death-row inmate using the drug midazolam hydrochloride, despite worries that it may not work as promised. Report
@FierceMedDev: Natera expands prenatal test amid global push. ICYMI yesterday | Follow @FierceMedDev
@MarkHFierce: Who are this year's FMD Fierce 15 winners? Find out here | Follow @MarkHFierce
@MichaelGFierce: Critical Diagnostics launches point-of-care cardiac disease test. Item | Follow @MichaelGFierce
> Covidien PAD treatments show promise in two trials. Article
> J&J's med tech biz falters amid weak sales, M&A rumors. Story
> Senate debt, government funding compromise avoids addressing device tax repeal. Report
Biotech News
@FierceBiotech: Analysts offer giddy forecasts for booming cancer immunotherapy pipeline. More | Follow @FierceBiotech
@JohnCFierce: PhIII blunders that have helped define companies, for better or worse. The top Phase III R&D setbacks of 2013 | Follow @JohnCFierce
@DamianFierce: If Myriad was a big dog in a small park in its fight with Ambry and Gene by Gene, Quest is a dog colossus. | Follow @DamianFierce
> Billionaire-backed immatics bags $46M to wrap cancer vaccine PhIII. Story
> JDRF, PureTech launch diabetes startup initiative. More
> AstraZeneca buys Spirogen in $440M deal, inks pact in armed antibody double-play. Story
> Aerie Pharma craves $84.5M in amped-up offering as IPOs pour in. More
> Sanofi plots more cuts at slow-footed French R&D shop. Article
Biotech Research News
@EmilyMFierce: Parkinson's may take two forms, one more toxic than the other. More | Follow @EmilyMFierce
> Vegetable-based compound protects against side effects of radiation therapy. Story
> Evotec gets $5.4M from Boehringer Ingelheim in cancer research pact. Report
> Compound halts neurodegeneration in mice. More
> Gene therapy plus stem cells quickens wound healing. Article
> Boston University, MRC Technology developing anti-inflammatory antibody. Item
Pharma Manufacturing News
@EricPFierce: MHRA says it also took action against Wockhardt contractor Nestor in U.K. as part of recent action. Article | Follow @EricPFierce
> U.S. awards special status to fired Novartis workers. Report
> Israeli unions threaten strikes over Teva job cuts. Item
> FDA closes out inspection on Ranbaxy New Jersey plant. More
> SAFC adds biologics capabilities at 2 plants. News
> Roche expanding biologics production in 3 countries. Story
And Finally... Can grandma's knees predict the weather? Scientists think they might. Report